Randomized, Double-blind, Placebo-controlled, Multicenter, Phase IIb Dose Finding Study of GLPG0634 Administered for 24 Weeks as Monotherapy to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (MTX) Alone

Trial Profile

Randomized, Double-blind, Placebo-controlled, Multicenter, Phase IIb Dose Finding Study of GLPG0634 Administered for 24 Weeks as Monotherapy to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (MTX) Alone

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Filgotinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms DARWIN-2
  • Sponsors Galapagos NV
  • Most Recent Events

    • 08 Nov 2017 Results of a post-hoc analysis two phase IIb studies (DARWIN-1 and DARWIN-2) assessing utility of a Multi Biomarker Disease Activity (MBDA) score in relation to clinical disease activity assessments in patients treated with filgotinib, were presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 08 Nov 2017 Results of a post-hoc analysis two phase IIb studies (DARWIN-1 and DARWIN-2) assessing association between normalization of patient-reported outcome measures (PRO) and clinical response (ACR20) in MTX-IR RA patients treated with either filgotinib or placebo, were presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 08 Nov 2017 Results of a post-hoc analysis two phase IIb studies (DARWIN-1 and DARWIN-2) assessing the effect of baseline serum CRP levels on clinical efficacy of Filgotinib, presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top